A Department of Defense (DoD)-funded Phase I/II clinical study on TapImmune's HER2/neu-targeted T-cell vaccine for women diagnosed with an early form of breast cancer called ductal carcinoma in situ (DCIS)
Phase of Trial: Phase I/II
Latest Information Update: 31 Aug 2017
At a glance
- Drugs TPIV 110 (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 31 Aug 2017 According to a TapImmune media release, the company plans to initiate a Phase 1b/2a clinical trial of TPIV 110 for treating women with HER2/neu+ breast cancer once an amended investigational new drug application (IND) is completed by year-end 2017 and upon FDA acceptance of the amended IND.
- 17 Mar 2017 New trial record
- 14 Mar 2017 This study is expected to begin in 2017 and will be led by Keith Knutson, according to a TapImmune media release.